Skip to main content
Top
Published in: Advances in Therapy 11/2020

Open Access 01-11-2020 | Mood Disorders | Original Research

Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis

Authors: Aki Shiozawa, Sari Hopson, Rupali Fuldeore, Matthias Stoelzel, Daniel Ng, John Hairston

Published in: Advances in Therapy | Issue 11/2020

Login to get access

Abstract

Introduction

This study sought to compare healthcare resource utilization (HCRU), costs, and workplace productivity among patients with depression, with and without overactive bladder (OAB).

Methods

This retrospective, case–control cohort analysis compares HCRU, costs, and workplace productivity among propensity score matched patients with depression and OAB (case cohort) and patients with depression without OAB (control cohort). Patients were aged 18 years or older, insured/on Medicare, and had diagnosed depression and an antidepressant medication claim pre index. First OAB-related event was index for cases; controls were assigned a proxy (study period 12 months). Comparisons of HCRU and costs and regression models assessed the relationship between OAB and costs. For the workplace productivity subset analyses cases and controls were balanced on baseline covariates for the short-term disability analyses but as they were unbalanced for the absentee analyses, multivariate regression analyses were used for this subset.

Results

The study criteria were met by 39,085 cases and 308,736 controls, from which, 37,997 patients were successfully matched 1:1 (mean age 55 years; 81% female). Most depression-related HCRU measures were similar across cohorts; however, outpatient visits, ER visits, and number of unique depression medications were significantly higher (all p < 0.05) among cases. Cases also had 13% higher total depression-related costs (p < 0.0001). Total mean (standard deviation [SD]) depression-related costs were $1796 ($4235) for cases versus $1597 ($3863) for controls (p < 0.0001). For workplace productivity (absentee data: cases [n = 686], controls [n = 642]; short-term disability data: cases [n = 4395], controls [n = 4433]) absentee outcomes were similar across cohorts. However, a higher percentage of cases used short-term disability benefits compared to controls (21.3% versus 16.9%; p < 0.0001) and cases experienced more case days (11.0 versus 8.6 mean days) and received higher mean payments than controls ($1226 versus $1033; p < 0.0001) in this subset.

Conclusions

OAB was associated with 13% higher depression-related costs and 4.4% more cases used short-term disability benefits.
Appendix
Available only for authorised users
Literature
2.
go back to reference Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nature Rev Disease Primers. 2016;2:16065.CrossRef Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nature Rev Disease Primers. 2016;2:16065.CrossRef
3.
go back to reference Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90.CrossRef Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90.CrossRef
4.
go back to reference Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the global burden of disease study 2010. PLoS One. 2013;8(7):e69637.CrossRef Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the global burden of disease study 2010. PLoS One. 2013;8(7):e69637.CrossRef
5.
go back to reference Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–62.CrossRef Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–62.CrossRef
6.
go back to reference Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12 (discussion 12).CrossRef Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12 (discussion 12).CrossRef
7.
go back to reference Stewart W, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.CrossRef Stewart W, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.CrossRef
8.
go back to reference Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Managed Care. 2009;15(4 Suppl):S90–7. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Managed Care. 2009;15(4 Suppl):S90–7.
9.
go back to reference Caplan EO, Abbass IM, Suehs BT, Ng DB, Gooch K, van Amerongen D. Impact of coexisting overactive bladder in medicare patients with dementia on clinical and economic outcomes. Am J Alzheimers Dis Other Demen. 2019;2019:1533317519841164. Caplan EO, Abbass IM, Suehs BT, Ng DB, Gooch K, van Amerongen D. Impact of coexisting overactive bladder in medicare patients with dementia on clinical and economic outcomes. Am J Alzheimers Dis Other Demen. 2019;2019:1533317519841164.
10.
go back to reference Caplan EO, Abbass IM, Suehs BT, et al. Impact of coexisting overactive bladder in Medicare patients with osteoporosis. Arch Gerontol Geriatr. 2018;75:44–50.CrossRef Caplan EO, Abbass IM, Suehs BT, et al. Impact of coexisting overactive bladder in Medicare patients with osteoporosis. Arch Gerontol Geriatr. 2018;75:44–50.CrossRef
11.
go back to reference Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy J Hum Pharmacol Drug Therapy. 2005;25(4):511–9.CrossRef Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy J Hum Pharmacol Drug Therapy. 2005;25(4):511–9.CrossRef
12.
go back to reference Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16(1):60.CrossRef Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16(1):60.CrossRef
13.
go back to reference Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–6.CrossRef Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–6.CrossRef
14.
go back to reference Nicolson P, Kopp Z, Chapple CR, Kelleher C. It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008;13(Pt 2):343–59.CrossRef Nicolson P, Kopp Z, Chapple CR, Kelleher C. It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008;13(Pt 2):343–59.CrossRef
15.
go back to reference Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32.CrossRef Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32.CrossRef
16.
go back to reference Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48(4):413–6.CrossRef Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48(4):413–6.CrossRef
17.
go back to reference Harvey R, Jankus DD, Mosley D. Random assignment of proxy event dates to unexposed controls in observational studies: an automated technique using SAS. Presented at the annual Midwest SAS Users Group, Minneapolis, MN. 2012. Harvey R, Jankus DD, Mosley D. Random assignment of proxy event dates to unexposed controls in observational studies: an automated technique using SAS. Presented at the annual Midwest SAS Users Group, Minneapolis, MN. 2012.
18.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRef Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRef
19.
go back to reference Yehoshua A, Chancellor M, Vasavada S, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406–13.PubMed Yehoshua A, Chancellor M, Vasavada S, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406–13.PubMed
20.
go back to reference Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103(2):202–9.CrossRef Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103(2):202–9.CrossRef
21.
go back to reference Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007;98(1–2):29–43.CrossRef Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007;98(1–2):29–43.CrossRef
22.
go back to reference Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–84.CrossRef Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–84.CrossRef
23.
go back to reference Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatric Serv. 2009;60(12):1604–11.CrossRef Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatric Serv. 2009;60(12):1604–11.CrossRef
24.
go back to reference Caplan EO, Abbass IM, Suehs BT, Ng DB, Gooch K, van Amerongen D. Impact of coexisting overactive bladder in medicare patients with dementia on clinical and economic outcomes. Am J Alzheimers Dis Other Demen. 2019;34(7–8):492–9.CrossRef Caplan EO, Abbass IM, Suehs BT, Ng DB, Gooch K, van Amerongen D. Impact of coexisting overactive bladder in medicare patients with dementia on clinical and economic outcomes. Am J Alzheimers Dis Other Demen. 2019;34(7–8):492–9.CrossRef
25.
go back to reference Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6S):2455–63.CrossRef Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6S):2455–63.CrossRef
26.
go back to reference Armstrong C. APA releases guidelines on treatment of patients with major depressive disorder. Am Fam Physician. 2011;83(10):1219. Armstrong C. APA releases guidelines on treatment of patients with major depressive disorder. Am Fam Physician. 2011;83(10):1219.
27.
go back to reference Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.CrossRef Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.CrossRef
28.
go back to reference Szabo SM, Gooch K, Schermer C, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5):e026391.CrossRef Szabo SM, Gooch K, Schermer C, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5):e026391.CrossRef
29.
go back to reference Lozano-Ortega G, Schermer CR, Walker DR, et al. Fall/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon Open. 2020;2020:1–11. Lozano-Ortega G, Schermer CR, Walker DR, et al. Fall/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon Open. 2020;2020:1–11.
Metadata
Title
Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis
Authors
Aki Shiozawa
Sari Hopson
Rupali Fuldeore
Matthias Stoelzel
Daniel Ng
John Hairston
Publication date
01-11-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 11/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01485-w

Other articles of this Issue 11/2020

Advances in Therapy 11/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.